Analyst Price Targets — MED
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:13 pm | — | Stephens | $12.00 | $10.71 | TheFly | Medifast price target lowered to $12 from $15 at Stephens |
| November 5, 2024 12:41 pm | Linda Bolton Weiser | D.A. Davidson | $17.00 | $20.40 | StreetInsider | DA Davidson Upgrades Medifast (MED) to Neutral |
| June 5, 2024 6:07 am | Linda Bolton Weiser | D.A. Davidson | $17.50 | $23.97 | StreetInsider | DA Davidson Downgrades Medifast (MED) to Underperform |
| April 30, 2024 5:00 am | Linda Bolton Weiser | D.A. Davidson | $25.00 | $35.51 | StreetInsider | Medifast (MED) PT Lowered to $25 at DA Davidson |
| June 5, 2023 9:09 am | Stephanie Wissink | Jefferies | $150.00 | $81.22 | Benzinga | Wall Street's Most Accurate Analysts Say Hold These 3 Defensive Stocks With Over 6% Dividend Yields |
| April 6, 2023 8:52 am | Linda Bolton Weiser | D.A. Davidson | $94.00 | $96.39 | Benzinga | Check Out 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street's Most Accurate Analysts |
Latest News for MED
BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and…
Medifast (NYSE: MED) reported fourth-quarter and full-year 2025 results while outlining continued efforts to reposition the business around metabolic health, highlighting early signs of improving coach productivity even as revenue and the active earning coach base declined sharply. Leadership transition and strategic focus Chairman and CEO Dan Chard said he plans to step down as chief
MED posts a wider quarterly loss as revenue tumbles 36.9% on a sharp drop in OPTAVIA coaches, despite beating revenue estimates.
Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MED.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.